Intensity Therapeutics, Inc. (INTS): Cash & Equivalents
$11.92M
As of 2025-12-31
$9.53M
As of 2026-06-30
+108.7%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.92M | +360.3% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $2.59M | -69.7% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $8.56M | +552.1% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $1.31M | n/a | 2024-03-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $11.92M | +360.3% |
| MiNK Therapeutics, Inc. (INKT) | 2025-12-31 | $13.36M | +191.9% |
| BioAtla, Inc. (BCAB) | 2025-12-31 | $7.12M | -85.5% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
Compare INTS, INKT, BCAB, ENTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗